The news of Oppenheimer maintaining an Outperform rating and raising the price target for Aptose Biosciences from $9 to $50 is a strong positive signal for the stock. This indicates that the analyst believes the company's prospects are improving and the stock is likely to outperform the market in the short term. This news is highly relevant and important for investors in APTO, as it directly affects their investment decisions and the stock's potential returns.